Newsroom
Stay informed on our latest company updates, scientific advancements, clinical milestones, and corporate announcements as we continue advancing NLRP3-based medicines.
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796
NodThera’s Oral NLRP3 Inhibitor NT-0796 Enhances and Sustains Weight Loss in Combination with GLP-1
The Future Of Inflammation: The Inflammasome And Beyond
In Vivo
Introducing Fierce Biotech’s 2024 Fierce 15
Fierce Biotech
Breaking the Cycle of Inflammation in Parkinson’s Disease
BioSpace
What do Parkinson’s and obesity have in common?
STAT